quinazolines has been researched along with acrylamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, M; Li, L; Li, Y; Liu, W; Liu, Z; Ma, X; Wang, L; Yi, Y; Zhang, W | 1 |
| Ahmad, I; Ansari, A; Belamkar, S; Nath Kundu, C; Nayak, D; Patel, H; Patil, C; Pawara, R; Surana, S; Wadkar, A; Wagh, S | 1 |
2 other study(ies) available for quinazolines and acrylamide
| Article | Year |
|---|---|
New acrylamide-substituted quinazoline derivatives with enhanced potency for the treatment of EGFR T790M-mutant non-small-cell lung cancers.
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2018 |
Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Topics: Acrylamide; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2021 |